547 / 1481
Dose de-escalation
Nevens et al.
Radiother Oncol
2017:Mar 22.
•
233 patients (3 prospective clinical trials):
•
SCC of head-and-neck
•
IMRT
±
concurrent chemo
•
Elective neck irradiation:
•
40 Gy (EQD2Gy)
•
Median follow-up 26 months
•
Regional control 89.2% at 2 years
•
Isolated regional recurrence in the “elective” neck 1/233 pts (0.4%)
•
Recurrence rates in the “elective” neck 3.9% at 2 years